Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7826338 | 0.82 | ACE (0.39) | P2RX7ACERORCCYP3A4CYP2C8 | |
| SCHEMBL10754807 | 0.82 | ACE (0.39) | P2RX7ACERORCCYP3A4CYP2C8 | |
| SCHEMBL20077497 | 0.81 | RORC (0.35) | P2RX7RORCCYP3A4CYP2C8ALDH1A1 | |
| SCHEMBL23253587 | 0.74 | P2RX7 (0.38) | P2RX7ACE | |
| SCHEMBL23230349 | 0.73 | P2RX7 (0.42) | P2RX7ACE | |
| SCHEMBL10689723 | 0.70 | PTGER4 (0.32) | RORC | |
| SCHEMBL10632319 | 0.70 | P2RX7 (0.41) | P2RX7ACEALDH1A1 | |
| SCHEMBL10632316 | 0.70 | P2RX7 (0.41) | P2RX7ACEALDH1A1 | |
| SCHEMBL10689728 | 0.70 | PTGER4 (0.32) | RORC | |
| SCHEMBL6706546 | 0.66 | ACE (0.41) | P2RX7ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300523-A1 | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | P2RX7 814/4885ACE 3546/4885RORC 1/4885 |
| US-10934286-B2 | Heterocyclic sulfones as ROR gamma modulators | RORC, RORB, RORA | P2RX7 814/4885ACE 3546/4885RORC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.